By: Benzinga
December 24, 2012 at 12:21 PM EST
UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion Pharmaceuticals
In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised its price target from $28.00 to $30.00. J.P. Morgan noted, “We are reiterating our OW rating on AEGR following FDA approval of Juxtapid (lomitapide) for HoFH, a potentially fatal
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here